Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …

Targeted delivery of therapeutic molecules into cancer cells is considered as a promising
strategy to tackle cancer. Antibody–drug conjugates (ADCs), in which a monoclonal …

Multiple myeloma (MM) is a B cell malignancy resulting in osteolytic lesions and fractures. In
the disease state, bone healing is limited owing to increased osteoclastic and decreased …

The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer
treatment in the past decade, both in oncology and hematology. The transfer of the …

Cancer is one of the leading causes of death worldwide due to high heterogeneity. Although
chemotherapy remains the mainstay of cancer therapy, non-selective toxicity and drug …

In this review, we have attempted to describe all of the antibody–drug conjugates using a
marine-derived compound as the “warhead”, that are currently in clinical trials as listed in the …

Progress in cancer research is substantially dependent on innovative technologies that
permit a concerted analysis of the tumor microenvironment and the cellular phenotypes …

Mass spectrometry (MS) is an essential analytical technology on which the emerging omics
domains; such as genomics; transcriptomics; proteomics and metabolomics; are based. This …

During ontogeny, hematopoietic stem and progenitor cells arise from hemogenic
endothelium through an endothelial-to-hematopoietic transition that is strictly dependent on …

Therapeutic monoclonal antibodies (mAbs) such as antibody–drug conjugates, ligand–
receptor antagonists, immune checkpoint inhibitors and bispecific T cell engagers have …